Biodesix, Inc. (NASDAQ:BDSX) Stock Upgrade and Financial Performance
Biodesix(US:BDSX) Financial Modeling Prep·2026-02-27 14:00William Blair upgraded NASDAQ:BDSX from Market Perform to Outperform, with a significant improvement in financial metrics.Biodesix reported a quarterly loss of $0.49 per share, beating the expected loss of $1.05, and achieved a revenue of $28.76 million, surpassing estimates by 14.11%.The company forecasts a revenue guidance for fiscal year 2026 between $106 to $112 million, indicating a 23% growth.Biodesix, Inc. (NASDAQ:BDSX) is a diagnostic solutions company that operates within the Zacks Medical Services ...